Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Pittsburgh, Pennsylvania

Cancer biologic therapy trials in Pittsburgh, PA

48 cancer biologic therapy studies are recruiting participants at sites in Pittsburgh as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Pittsburgh at a glance

  • 48 studies are recruiting at a site in Pittsburgh.
  • By phase: Early Phase 1 (1), Phase 1 (6), Phase 1/2 (11), Phase 2 (14), Phase 2/3 (2), Phase 3 (14).
  • By sponsor: industry (18), government (15), university, hospital or other (15).
  • By research area: Lung Cancer (15), Breast Cancer (10), Melanoma (10), Lymphoma (9), Prostate Cancer (3), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Pittsburgh

Basic details from each study's public record (the 30 most recently updated of 48). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT03606967 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital · UPMC-Passavant Hospital
    Registry record
    NCT05564377 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
    Registry record
    NCT06058377 · updated
  4. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058)
    Registry record
    NCT07060807 · updated
  5. Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Finn, Olivera, PhD
    Study site
    UPMC Magee Womens Hospital
    Registry record
    NCT06218303 · updated
  6. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Allegheny General Hospital · UPMC Hillman Cancer Center · UPMC-Magee Womens Hospital
    Registry record
    NCT06876714 · updated
  7. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05877599 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lung cancer studies recruiting in Pittsburgh

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  3. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06287775 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Mercy Hospital · UPMC-Passavant Hospital
    Registry record
    NCT04267848 · updated
  5. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Study site
    Allegheny Research Institute (Melanoma/NSCLC)
    Registry record
    NCT06060613 · updated
  6. Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Olivera Finn
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT01720836 · updated
  7. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06031688 · updated
  8. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Margaret
    Registry record
    NCT06116682 · updated
  9. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Clair Hospital Cancer Center
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Pittsburgh

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UPMC Hillman Cancer Center · UPMC-Passavant Hospital · UPMC-Saint Clair Hospital Cancer Center
    Registry record
    NCT03866382 · updated
  2. A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    UPMC Cancer Centers
    Registry record
    NCT07164443 · updated
  3. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Melanoma studies recruiting in Pittsburgh

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06743126 · updated
  2. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05896839 · updated
  3. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

    • Phase 3
    • Ages 18 to 70
    • All sexes
    Sponsor
    Iovance Biotherapeutics, Inc.
    Study site
    Allegheny Health Network
    Registry record
    NCT05727904 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lymphoma studies recruiting in Pittsburgh

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT06317662 · updated
  2. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT04546399 · updated
  3. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT05675410 · updated
  4. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07003295 · updated
  5. Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Allogene Therapeutics
    Study site
    West Penn Hospital
    Registry record
    NCT06500273 · updated
  6. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT06124157 · updated
  7. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    • Phase 2
    • Ages 1 to 60
    • All sexes
    Sponsor
    Fred Hutchinson Cancer Center
    Study site
    University of Pittsburgh Cancer Institute (UPCI)
    Registry record
    NCT03970096 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Pittsburgh

  1. Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07619521 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Ask about studies near Pittsburgh

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call